Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate

Archives of Medical Science

Volumn 9, Issue 2, 2013, Pages 238-242

  Cicero, Arrigo F G ^a   Derosa, Giuseppe ^b   Maffioli, Pamela ^a   Reggi, Alessandra ^b   Grandi, Elisa ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Epidemiology; Familial combined hyperlipoproteinemia; Metabolic syndrome; Prevalence; Prognosis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84876932873     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.34537     Document Type: Article

References (27)

1. Gaddi AV, Cicero AFG, Odoo FO, Poli A, Paoletti R; the Atherosclerosis and Metabolic Diseases Study Group. Practical reccomendations for familial combined hyperlipidemia diagnosis and management: an update. Vasc Dis Prev 2007; 4: 229-36. (Pubitemid 47235981)
2. Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia - Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32: 71-3.
3. Sniderman AD, Ribalta J, Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases? Nutr Metab Cardiovasc Dis 2001; 11: 259-73. (Pubitemid 33686216)
4. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13: 427-34. (Pubitemid 23075633)
5. Keulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 2002; 22: 283-8. (Pubitemid 34127040)
6. Brouwers MC, Reesink KD, van Greevenbroek MM, et al. Increased arterial stiffness in familial combined hyperlipidemia. J Hypertens 2009; 27: 1009-16.
7. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 2002; 33: 1255-60. (Pubitemid 34517044)
8. Pitkanen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999; 99: 1678-84. (Pubitemid 29162479)
9. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000; 101: 2777-82. (Pubitemid 30396006)
10. Cicero AFG, Bove M, Manca M, Borghi C, Gaddi AV. Detection of familial combined hyperlipoproteinemia patients in the Brisighella Heart Study historical cohort: an epidemiological approach. J Inherit Metab Dis 2007; 30: 268. (Pubitemid 46488009)
11. Gaddi AV, Cicero AFG, Odoo FO, Poli A, Paoletti R; the Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag 2007; 3: 877-86.
12. De Bruin TWA, Castro Cabezas M, Dallinga-Yhie G, Erkelens DW. Familial combined hyperlipidaemia - do we understand the pathophysiology and genetics? In: Lipids: current perspectives. Betteridge DJ (ed.). Martin Dunitz, London 1996; 101-9.
13. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA; Conference Participants. Clinical Management of Metabolic Syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004; 109: 551-6. (Pubitemid 38168522)
14. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-97.
15. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519-23. (Pubitemid 36961163)
16. Cicero AF, Derosa G, D'angelo A, Bove M, Gaddi AV, Borghi C. Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. Blood Press 2009; 18: 111-6.
17. Nasir K, Budoff MJ, Wong ND, et al. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007; 116: 619-26. (Pubitemid 47356346)
18. Cicero AFG, Dormi A, D'Addato S, Gaddi AV, Borghi C; the Brisighella Heart Study Group. Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: The Brisighella Heart Study. J Women Health 2010; 19: 133-7.
19. Shoulders CC, Naoumova RP. USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome. Trends Mol Med 2004; 10: 362-5. (Pubitemid 39061136)
20. Georgieva AM, Cate HT, Keulen ET, et al. Prothrombotic markers in familial combined hyperlipidemia. Evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis 2004; 175: 345-51. (Pubitemid 38942915)
21. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 195561.
22. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000; 101: 2777-82. (Pubitemid 30396006)
23. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23: 1289-94. (Pubitemid 36871286)
24. Delawi D, Meijssen S, Castro Cabezas M. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta 2003; 328: 139-45. (Pubitemid 36138812)
25. Rynkiewicz A, Cybulska B, Banach M, et al. Management of familial heterozygous hypercholesterolemia: position paper of the Polish Lipid Expert Forum. J Clin Lipidol 2013; DOI: 10.1016/j.jacl.2013.01.005.
26. Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 2011; 7: 8-20.
27. Pavlidis AN, Kolovou GD, Anagnostopoulou KK, Petrou PC, Cokkinos DV. Postprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch Med Sci 2010; 6: 879-86.